mRECIST for systemic therapies: More evidence is required before recommendations can be made

We read we great interest the article by Lencioni et al. entitled “Objective response by mRECIST as a predictor and potential surrogate endpoint of overall survival in advanced HCC” [ [1] Lencioni R. Montal R. Torres F. Park J.W. Decaens T. Raoul J.L. et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol. 2017; 66: 1166-1172 Abstract Full Text Full Text PDF PubMed Scopus (140) Google Scholar ]. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCCJournal of HepatologyVol. 66Issue 6PreviewIn 60% of cases, patients with hepatocellular carcinoma (HCC) are diagnosed when tumors are no longer eligible for potentially curative therapies [1]. In this setting, only two treatments have been included in guidelines after demonstrating survival advantages in randomized controlled trials. Patients at an intermediate stage benefit from chemoembolization and have an estimated median overall survival (OS) of 26 months [2], while at advanced stages, sorafenib extends survival from 8 to almost 11 months [3]. Full-Text PDF Reply to: “mRECIST for systemic therapies: More evidence is required before recommendations could be made”Journal of HepatologyVol. 67Issue 1PreviewWe appreciate the interest generated by our manuscript, and thank the letter by Dr. Edeline et al. [1] and the Editor for the opportunity of responding. Full-Text PDF